Adaptive Biotechnologies (ADPT) Tops Q3 EPS by 2c; Reports Cash and Cash Equivalents of $632.4M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Adaptive Biotechnologies Reports Third Quarter 2021 Financial Results
November 3, 2021 4:05 PM EDTSEATTLE, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Adaptive Biotechnologies) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2021.
We are pleased to deliver another quarter of strong growth with continued momentum across research, diagnostic and drug discovery, said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. Achievements during the quarter mark important advancements in the evolution of our immune medicine platform as a clinical product development engine.
... More